ACCESS TO INFORMATION;
ALZHEIMER DISEASE;
CLINICAL TRIAL;
DRUG DESIGN;
DRUG EFFICACY;
DRUG INFORMATION;
DRUG PROGRAM;
DRUG QUALITY;
DRUG RESEARCH;
DRUG SCREENING;
EDITORIAL;
EUROPE;
FRANCE;
HIGH THROUGHPUT SCREENING;
HUMAN;
INTERDISCIPLINARY RESEARCH;
MOLECULAR PROBE;
PATENT;
PHARMACOPHORE;
COMBINATORIAL CHEMISTRY TECHNIQUES;
COOPERATIVE BEHAVIOR;
DRUG DISCOVERY;
EUROPE;
FRANCE;
PLANT EXTRACTS;
SMALL MOLECULE LIBRARIES;
3D-QSAR and docking studies of selective GSK-3 inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3 ligands
Lescot E., et al. 3D-QSAR and docking studies of selective GSK-3 inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3 ligands. J. Chem. Inf. Model. 45 (2005) 708-715
New biologically active linear triterpenes from the bark of three new-caledonian Cupaniopsis species
Bousserouel H., et al. New biologically active linear triterpenes from the bark of three new-caledonian Cupaniopsis species. Tetrahedron 61 (2005) 845-851
Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers
Monge A., et al. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers. 10 (2006) 389-403
Use of a fluorescent polarization based high throughput assay to identify new calmodulin ligands
Dagher R., et al. Use of a fluorescent polarization based high throughput assay to identify new calmodulin ligands. Biochim. Biophys. Acta 1763 (2006) 1250-1255
Hibert, M. et al. (2006) Domain therapeutics. Collections of traceable compounds and uses thereof. WO2006003329
Hibert, M. et al. (2006) Domain therapeutics. Collections of traceable compounds and uses thereof. WO2006003329
9
34347395367
A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties
Maillet E., et al. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J. 21 (2007) 2124-2134
Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors
Soret J., et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8764-8769
Transition therapeutics. Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
US2003176437
Watterson, M.D. et al. (2003) Transition therapeutics. Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death. US2003176437
